NexoBrid FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 17, 2023.
FDA Approved: Yes (First approved December 28, 2022)
Brand name: NexoBrid
Generic name: anacaulase-bcdb
Dosage form: for Topical Gel
Company: MediWound Ltd.
Treatment for: Thermal Burn
NexoBrid (anacaulase-bcdb) is a concentrate of proteolytic enzymes indicated for removal of eschar in adults with deep partial- and full-thickness thermal burns.
- NexoBrid should only be applied by trained healthcare professionals in specialist burn centres.
- NexoBrid powder is mixed with a gel to form a uniform gel and applied to a clean, keratin-free (blisters removed), and moist wound area.
- NexoBrid can be applied in up to two applications of four hours each. A first application of NexoBrid may be applied to an area of up to 15% body surface area. A second application of NexoBrid may be applied 24 hours later, with a total treated area for both applications of up to 20% body surface area.
- Warnings and precautions associated with NexoBrid include hypersensitivity reactions, management of pain during dressing changes, and coagulation abnormalities.
- Common adverse reactions include pruritus and pyrexia.
Development timeline for NexoBrid
| Date | Article |
|---|---|
| Dec 29, 2022 | Approval FDA Approves NexoBrid (anacaulase-bcdb) for the Treatment of Severe Thermal Burns in Adults |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
